Keystone Biologics reports successful non-clinical proof of concept for pipeline drug

In a non-clinical proof-of-concept study sponsored by Keystone Biologics, moderate to severe ulcerative colitis was induced in animals under controlled conditions. The animals were then dosed with either kPPF1 or a vehicle control. The results demonstrated the following:

1. Animals with moderate to severe ulcerative colitis demonstrated a statistically significant decrease of a protein thought to be necessary for the alleviation of inflammation in the colon.
2. Animals receiving kPPF1 showed a statistically significant increase, up to normal values of this protein.
3. Animals receiving kPPF1showed a statistically significant decrease in colon histology scores, indicating the alleviation of ulcerative colitis symptoms, as compared with control animals after 10 days of therapy.

Keystone Biologics receives $244,000 grant from the Qualified Therapeutic Discovery Project

The Qualified Therapeutic Discovery Project (QTDP) program is part of the Patient Protection and Affordable Care Act of 2010 and provides a 50% tax credit or grant to biotech, pharmaceutical and other healthcare companies for qualified investments. Keystone Biologics was selected from the more than 7000 companies that applied for the grants.